Company intelligence / Profile preview

Rebiotix Inc.

Roseville, Minnesota, United Statesrebiotix.com ↗

Ownership: Private
Development stage: Other

Overview

Completed enrollment for pivotal Phase 3 clinical trial of RBX2660 for recurrent C. diff infection. RBX2660 has received FDA Fast Track, Breakthrough Therapy, and Orphan Drug Designations.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Microbiota-based therapiesLive biotherapeutics
Industry: Biotech

Drug pipeline

2 assets

fecal microbiota for transplantation

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Ferring Pharmaceuticals (now parent company)

Beyond the preview

Go deeper on Rebiotix Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rebiotix Inc..

Explore the full profile